HRIM vs Mucosal Impedance in GERD Participants

Baseline Impedance Measured on High Resolution Esophageal Impedance Manometry to Discriminate GERD From Non GERD Patients

NCT02812407•Mayo Clinic

View on ClinicalTrials.gov

Summary

Does baseline impedance measured during the landmark phase of esophageal High resolution impedance manometry HRIM correlates with direct mucosal impedance measurement and discriminates GERD from non GERD patients?

Detailed Description

Patients referred to the Mayo Clinic Rochester for a clinically indicated high resolution impedance manometry (HRIM), 24 hour impedance pH (MII-pH) study, and esophagogastroduodenoscopy (EGD) will be recruited. Gastroesophageal reflux will be defined as a total 24 hour esophageal acid exposure time ≥5% regardless of concomitant Proton Pump inhibitor (PPI) use. A negative 24 hour MII-pH study will be defined as an acid exposure time ≤2% off PPI therapy or ≤1% if on PPI therapy.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients being seen at Mayo clinic Rochester having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.
•Adults ages 18-90
•Patients scheduled for or have completed a HRIM ( within 5 days)
•Patients scheduled for or recently have completed a MII-pH studies ( within 5 days)
•Patients scheduled for EGD

Exclusion Criteria

•Technically limited esophageal HRIM or MII-pH study
•Patients with HRIM and MII-pH studies not performed within 5 days of each other
•Patients with EGD not performed within 30 days of HRIM and MII-pH studies
•Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy
•Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

June 1, 2016

Primary Completion Date

August 1, 2019

Completion Date

August 1, 2019

Last Updated

June 9, 2020

Conditions

Gastro-esophageal Reflux Disease (GERD)

Interventions

Mucosal Impedance

DEVICE

FODMAPs and Refractory GERD

NCT02471989

Gastro-esophageal Reflux Disease (GERD)

View study

COMPLETEDPHASE3

Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

NCT02623062

Gastro-esophageal Reflux Disease (GERD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions